Prescribing Outlook 2020


Prescribing Outlook 2020 – combined chapters (163 pages)

Prescribing Outlook 2020 – spreadsheet version (new medicines, cancer therapies, biosimilars)

*Coming soon*
Prescribing Outlook 2020 – Cost Calculator

Foreword, acknowledgements, guidance notes, key and abbreviations
BNF 1. Gastro-intestinal system
BNF 2. Cardiovasular system
BNF 3. Respiratory system
BNF 4. Nervous system
BNF 5. Infections
BNF 6. Endocrine system
BNF 7. Genito-urinary system
BNF 8. Immunnosuppression (excluding cancer except if an ATMP)
BNF 8. Cancer therapies
BNF 9. Blood and nutrition
BNF 10. Musculoskeletal system
BNF 11. Eye
BNF 12. Ear, nose and oropharynx
BNF 13. Skin
BNF 14. Vaccines
BNF 15. Anaesthesia
Advanced therapy medicinal products (ATMPs)
Patent expiries
Recently launched medicines
Delayed medicines


Please note that only people with an NHS login will be able to access these documents (see below for details).

The Prescribing Outlook Series assists NHS budget holders and those involved in prescribing planning assess potential impact of new drugs and national guidance on the local health economy. The documents include information on drugs with launches planned over the next 12 to 18 months and on marketed drugs with new major indications as well as information on NICE guidance, NHS England and other national targets that may have budgetary implications over the next 18 months. It is intended to help implementation of national guidelines and to calculate cost of such implementation.

Prescribing Outlook New Medicines and National Developments, previously published as separate documents are now combined. The information is presented as separate chapters as well as one combined (large) document. Pipeline cancer therapies  and patent expiries are presented as separate Excel spreadsheets.

An Excel spreadsheet containing details of new medicines only will also be available.

Prescribing Outlook – cost calculator is an Excel spreadsheet based on content of New Medicines and National Developments. It allows crude calculations of potential costs of prescribing changes for a local population. It will be available in the near future as will a presentation containing an overview of the major prescribing developments with a primary care focus expected in the next 12 to 18 months. It contains information from the whole Prescribing Outlook series.

To access these documents you need to be logged into the SPS site. You can request registration (free to NHS staff) from the home page.  If you would like a copy of these documents but do not qualify for free access please submit your request to the SPS horizon scanning service at for consideration on a case by case basis (non-commercial only).

Please note that as these are restricted documents they should treated as such once downloaded and used for internal purposes only. The documents should not be uploaded to other websites although we are happy for external websites to contain hyperlinks to relevant SPS website pages.



The information in these resources is the best available at the time of writing but, in this rapidly changing field, is subject to significant change with time. Content that changed after 31st August 2020 is not included. Refer to hyperlinks throughout for the latest data.

The implications of the UK exit from Europe on the availability of new medicines and licence extensions in the UK is a factor that cannot yet be quantified and has therefore not been taken account of in these documents.

The financial assumptions are based on the opinions of the authors and are highly sensitive to variation of any one or all of the factors used to arrive at the statement.  Generally national figures have been used; use of local figures will increase the reliability of these estimates.

The authors do not accept responsibility for accuracy of documents that are derived from this original publication.

Right to copy  

These documents are produced by the NHS for the NHS and are intended for use by individual NHS organisations exclusively for internal use within that organisation.  The aim is to inform decisions about managed entry of new medicines and medicines management more generally within that organisation.  The data within these documents should not be used for commercial purposes or for any means of financial gain.

The documents, or content within them, should not be posted on any websites, copied or forwarded electronically outside your organisation, without the express permission of the executive editor. Please contact to request such permission.

If you download these documents you agree to abide by these conditions.